Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
immunology and microbiology
Short communication: Transmitted HIV drug resistance in antiretroviral-naive pregnant women in north central Nigeria
AIDS Research and Human Retroviruses, Volume 30, No. 2, Year 2014
Notification
URL copied to clipboard!
Description
The World Health Organization (WHO) recommends periodic surveillance of transmitted drug resistance (TDR) in communities in which antiretroviral therapy (ART) has been scaled-up for greater than 3 years. We conducted a survey of TDR mutations among newly detected HIV-infected antiretroviral (ARV)-naive pregnant women. From May 2010 to March 2012, 38 ARV-naive pregnant women were recruited in three hospitals in Jos, Plateau state, north central Nigeria. Eligible subjects were recruited using a modified version of the binomial sequential sampling technique recommended by WHO. HIV-1 genotyping was performed and HIV-1 drug resistance mutations were characterized according to the WHO 2009 surveillance drug resistance mutation (SDRM) list. HIV subtypes were determined by phylogenetic analysis. The women's median age was 25.5 years; the median CD4+ cell count was 317 cells/μl and the median viral load of 16 was 261 copies/ml. Of the 38 samples tested, 34 (89%) were successfully genotyped. The SDRM rate was <5% for all ART drug classes, with 1/34 (2.9%) for NRTIs/NNRTIs and none for protease inhibitors 0/31 (0%). The specific SDRMs detected were M41L for nucleoside reverse transcriptase inhibitors (NRTIs) and G190A for nonnucleoside reverse transcriptase inhibitors (NNRTIs). HIV-1 subtypes detected were CRF02-AG (38.2%), G′ (41.2%), G (14.7%), CRF06-CPX (2.9%), and a unique AG recombinant form (2.9%). The single ARV-native pregnant woman with SDRMs was infected with HIV-1 subtype G′. Access to ART has been available in the Jos area for over 8 years. The prevalence of TDR lower than 5% suggests proper ART administration, although continued surveillance is warranted. © Mary Ann Liebert, Inc.
Authors & Co-Authors
Imade, Godwin Eremwan
Nigeria, Jos
University of Jos
Sagay, Atiene Solomon
Nigeria, Jos
University of Jos
Chaplin, Beth R.
United States, Boston
Harvard T.h. Chan School of Public Health
Chebu, Philippe R.
Nigeria, Jos
University of Jos
Musa, Jonah
Nigeria, Jos
University of Jos
Okpokwu, Jonathan
Nigeria, Jos
University of Jos
Hamel, Donald J.
United States, Boston
Harvard T.h. Chan School of Public Health
Pam, Ishaya C.
Nigeria, Jos
University of Jos
Agbaji, Oche Ochai O.
Nigeria, Jos
University of Jos
Samuels, Jay
Nigeria, Abuja
Apin Public Health Initiatives Ltd./gte
Meloni, Seema Thakore
United States, Boston
Harvard T.h. Chan School of Public Health
Sankalé, Jean Louis G.
United States, Decatur
Globomics Llc
Okonkwo, Prosper I.
Nigeria, Abuja
Apin Public Health Initiatives Ltd./gte
Kanki, Phyllis Jean
United States, Boston
Harvard T.h. Chan School of Public Health
Statistics
Citations: 25
Authors: 14
Affiliations: 4
Identifiers
Doi:
10.1089/aid.2013.0074
ISSN:
08892229
e-ISSN:
19318405
Research Areas
Cancer
Health System And Policy
Infectious Diseases
Study Design
Cross Sectional Study
Study Approach
Quantitative
Study Locations
Nigeria
Participants Gender
Female